<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
pre
{mso-style-priority:99;
mso-style-link:"HTML Preformatted Char";
margin:0in;
margin-bottom:.0001pt;
font-size:10.0pt;
font-family:"Courier New";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.HTMLPreformattedChar
{mso-style-name:"HTML Preformatted Char";
mso-style-priority:99;
mso-style-link:"HTML Preformatted";
font-family:"Courier New";}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle23
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle25
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle26
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:177236407;
mso-list-type:hybrid;
mso-list-template-ids:1100535298 170394020 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
{mso-level-start-at:215;
mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:.75in;
text-indent:-.25in;
font-family:Symbol;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman";
color:windowtext;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:1.25in;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:1.75in;
text-indent:-.25in;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:2.25in;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:2.75in;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:3.25in;
text-indent:-.25in;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:3.75in;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:4.25in;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:4.75in;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal">*Español debajo*<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">Public Citizen has a new fact sheet on <a href="https://www.citizen.org/sites/default/files/a2m_nafta_factsheet.pdf">
NAFTA’s threats to access to medicines</a>. It’s also available <a href="https://www.citizen.org/sites/default/files/a2m_nafta_factsheet_-_espanol.pdf">
in Spanish here</a>. <o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">Please share from GTW:<o:p></o:p></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]>On Twitter: <span style="color:#1F497D"><a href="https://twitter.com/PCGTW/status/978636014204915712">English</a> |
<a href="https://twitter.com/PCGTW/status/978669742318907392">Spanish</a><o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]>On Facebook: <span style="color:#1F497D"><a href="https://www.facebook.com/GlobalTradeWatch/posts/2128284093868342">English</a> |
<a href="https://www.facebook.com/GlobalTradeWatch/posts/2128438547186230">Spanish</a><o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">Or you can make your own posts using the graphics attached. Here is some suggested language to go with them:
<o:p></o:p></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]>#BigPharma corporations and the Trump administration are pushing for #NAFTA rules that would lock in high #drugprices prices, especially for #cancer medicines. Info at:
<a href="http://bit.ly/nafta-a2m">bit.ly/nafta-a2m</a> <o:p></o:p></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]>NEW: Learn more about how #NAFTA renegotiation threatens access to lifesaving medicines.
<a href="http://bit.ly/nafta-a2m">bit.ly/nafta-a2m</a><o:p></o:p></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]>#NAFTA: #BigPharma’s latest tool to rake in profits and keep #drugprices sky-high. Here’s how:
<a href="http://bit.ly/nafta-a2m">bit.ly/nafta-a2m</a><o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">------<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">P<span lang="es-419">ublic Citizen publicó una nueva hoja informativa
</span><span class="MsoHyperlink"><a href="https://www.citizen.org/sites/default/files/a2m_nafta_factsheet_-_espanol.pdf"><span lang="es-419">en Español acerca de las amenazas del TLCAN para el acceso a las medicinas</span></a></span><span lang="es-419">. También
está disponible <a href="https://www.citizen.org/sites/default/files/a2m_nafta_factsheet.pdf">
en Inglés aquí</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="es-419"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="es-419">Por favor, comparta desde GTW:<o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span lang="es-419" style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="es-419">En Twitter: <a href="https://twitter.com/PCGTW/status/978669742318907392">
Español</a> | <a href="https://twitter.com/PCGTW/status/978636014204915712">Inglés</a><o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span lang="es-419" style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="es-419">En Facebook: <a href="https://www.facebook.com/GlobalTradeWatch/posts/2128438547186230">
Español</a> | <a href="https://www.facebook.com/GlobalTradeWatch/posts/2128284093868342">
Inglés</a><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="es-419"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="es-419">Si quieres, puedes compartirlo en tus redes sociales usando estas sugerencias:<o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span lang="es-419" style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="es-419">Las corporaciones #BigPharma y la administración Trump están presionando para que las reglas del #TLCAN aumenten los precios de las medicinas, especialmente para los medicamentos para el #cancer. Más Información:
<a href="bit.ly/2G9aaw6">bit.ly/2G9aaw6</a> <o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span lang="es-419" style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="es-419">NUEVO: Obtenga más información sobre cómo la renegociación del #TLCAN amenaza el acceso a la medicinas que salvan vidas.
<a href="bit.ly/2G9aaw6">bit.ly/2G9aaw6</a><o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo2">
<![if !supportLists]><span lang="es-419" style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="es-419">#TLCAN: la última herramienta de #BigPharma para obtener ganancias y mantener los precios de las drogas por las nubes. Ve aquí cómo lo hace:
<a href="bit.ly/2G9aaw6">bit.ly/2G9aaw6</a><o:p></o:p></span></p>
<p><o:p> </o:p></p>
</div>
</body>
</html>